WO2000000222A1 - Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents - Google Patents
Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents Download PDFInfo
- Publication number
- WO2000000222A1 WO2000000222A1 PCT/US1999/014206 US9914206W WO0000222A1 WO 2000000222 A1 WO2000000222 A1 WO 2000000222A1 US 9914206 W US9914206 W US 9914206W WO 0000222 A1 WO0000222 A1 WO 0000222A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- factor
- biologically active
- polymeric matrix
- poly
- leptin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Definitions
- thermosensitive, biodegradable hydrogels consisting of a block copolymer of poly(d,l- or 1- lactic acid) (PLA) or poly (lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG) , for the sustained delivery of biologically active agents.
- PLA poly(d,l- or 1- lactic acid)
- PLGA poly (lactide-co-glycolide)
- PEG polyethylene glycol
- proteins known to exhibit various pharmacological actions in vivo are capable of production in large amounts for pharmaceutical applications.
- Such proteins include erythropoietin (EPO) , granulocyte colony- stimulating factor (G-CSF) , interferons (alpha, beta, gamma, consensus) , tumor necrosis factor binding protein (TNFbp) , interleukin- 1 receptor antagonist (IL-lra), brain-derived neurotrophic factor (BDNF) , kerantinocyte growth factor (KGF) , stem cell factor (SCF) , megakaryocyte growth differentiation factor (MGDF) , osteoprotegerin (OPG) , glial cell line derived neurotrophic factor (GDNF) and obesity protein (OB protein) .
- EPO erythropoietin
- G-CSF granulocyte colony- stimulating factor
- interferons alpha, beta, gamma, consensus
- TNFbp tumor necrosis factor binding protein
- OB protein may also be referred to herein as leptin.
- proteins such as leptin generally have short in vivo half -lives and negligible oral bioavailability, they are typically administered by frequent injection, thus posing a significant physical burden on the patient (e.g., injection site reactions are particularly problematic with many leptin formulations) and associated administrative costs.
- sustained- release formulations can provide a means of controlling blood levels of the active ingredient, and also provide greater efficacy, safety, patient convenience and patient compliance.
- the instability of most proteins e.g. denaturation and loss of bioactivity upon exposure to heat, organic solvents, etc.
- Biodegradable polymer matrices have thus been evaluated as sustained- release delivery systems. Attempts to develop sustained- release formulations have included the use of a variety of biodegradable and non- biodegradable polymer (e.g. poly (lactide-co-glycolide) ) microparticles containing the active ingredient (see e.g., Wise et al . , Contraception, 8:227-234 (1973); and Hutchinson et al . , Biochem . Soc . Trans . , 13.: 520 -523
- biodegradable and non- biodegradable polymer e.g. poly (lactide-co-glycolide)
- microparticles containing the active ingredient see e.g., Wise et al . , Contraception, 8:227-234 (1973); and Hutchinson et al . , Biochem . Soc . Trans . , 13.: 520 -523
- Various problems identified with the use of such polymers include: inability of certain macromolecules to diffuse out through the matrix; deterioration and decomposition of the drug (e.g., denaturation caused by the use of organic solvents) ; irritation to the organism (e.g. side effects due to use of organic solvents) ; low biodegradability (such as that which occurs with polycondensation of a polymer with a multifunctional alcohol or multifunctional carboxylic acid, i.e., ointments); and slow rates of degradation.
- inability of certain macromolecules to diffuse out through the matrix deterioration and decomposition of the drug (e.g., denaturation caused by the use of organic solvents) ; irritation to the organism (e.g. side effects due to use of organic solvents) ; low biodegradability (such as that which occurs with polycondensation of a polymer with a multifunctional alcohol or multifunctional carboxylic acid, i.e., ointments); and slow rates of degradation.
- Cha et al. U.S. Patent No. 5,702,717 (Dec. 30, 1997) describe systems for parenteral delivery of a drug comprising an injectable biodegradable block copolymeric drug delivery liquid having reverse thermal gelation properties, i.e., ability to form semi -solid gel, emulsions or suspension at certain temperatures.
- these thermosensitive gels exist as a mobile viscous liquid at low temperatures, but form a rigid semisolid gel at higher temperatures.
- hydrophobic A polymer block comprising a member selected from the group consisting of poly ( ⁇ -hydroxy acids) and poly (ethylene carbonates) and a hydrophilic B polymer block comprising a PEG.
- the Cha et al . system requires that less than 50% by weight hydrophobic A polymer block be utilized and greater than 50% by weight hydrophilic B polymer block be utilized.
- LCST lower critical solution temperature
- thermosensitive, biodegradable hydrogels for the sustained delivery of drugs.
- the hydrogels of the present invention utilize copolymer compositions which provide for instant gelation, and which possess the necessary rate of degradation to make use of the hydrogels commercially practical.
- the present invention provides pharmaceutical compositions comprising an effective amount of a biologically active agent incorporated into a polymeric matrix, said polymeric matrix comprising a block copolymer which is biodegradable, exhibits thermal gelation behavior, and is capable of providing for the sustained- release of the biologically active agent.
- the present invention provides a method for the parenteral administration of a biologically active agent in a biodegradable polymeric matrix to a warm blooded animal, wherein a gel depot is formed within the body of said animal and the biologically active agent is released from the depot at a controlled rate concomitant with biodegradation of the polymeric matrix.
- FIG 1 depicts the two methods by which the
- A-B-A block copolymers of the present invention can be prepared.
- Figure 2 depicts the in vi tro release characteristics of leptin released from a hydrogel (PLGA/PEG (74%/26% w/w) ) . % protein released is plotted vs. time (days) .
- Figure 3 is a photograph of an SDS-PAGE gel characterizing samples of leptin released from a hydrogel on various days.
- Lane 1 is a leptin standard; Lane 2 and 15 contain molecular weight markers; and Lanes 3-14 represent leptin samples at day 1-12, respectively.
- Figure 4 depicts the in vivo bioactivity for various leptin-containing hydrogel (PLGA/PEG (74%/26% w/w)) formulations.
- the -*- depicts a 20mM acetate, pH 4.8, buffer control, lOO ⁇ l on day 0;
- -•- depicts a hydrogel (74%/26%) control, lOO ⁇ l on day 0;
- - ⁇ - depicts leptin (20 mg/mL) , 100 mg/kg, lOO ⁇ l on day 0;
- - ⁇ - depicts leptin (2 mg/mL) , 10 mg/kg, lOO ⁇ l daily;
- - A- depicts a leptin- containing hydrogel (PLGA/PEG (74%/26% w/w)), 20 mg/mL leptin, 100 mg/kg, lOO ⁇ l on day 0;
- - ⁇ - depicts a leptin-containing hydrogel (PLGA/PEG (74%/26% w/w)), 20 mg/mL leptin, 200 mg/kg,
- Figure 5 depicts the pharmacokinetics for a leptin- containing hydrogel (PLGA/PEG (74%/26% w/w)) (-A-) and leptin solution (- ⁇ -). Serum leptin concentration (ng/mL) is plotted vs. time (hours).
- Figure 6 depicts the in vi tro release characteristics for GCSF from a GCSF-containing hydrogel (PLGA/PEG (74%/26% w/w)) (- ⁇ -) and Fc-OPG from a Fc-OPG-containing hydrogel (PLGA/PEG (74%/26% w/w)) (- ⁇ -). % protein released is plotted vs. time (days).
- Figure 7 is a photograph of an SDS-PAGE gel characterizing samples of GCSF released from a hydrogel on various days.
- Lane 1 is a leptin standard; Lane 2 and 15 contain molecular weight markers; and Lanes 3-14 represent leptin samples at day 1-12, respectively.
- Figure 8 depicts the in vivo bioactivity for a Zn: leptin- containing hydrogel (PLGA/PEG (74%/26% w/w)) formulation.
- -*- depicts a 20mM acetate, pH 4.8, buffer control, lOO ⁇ l on day 0;
- -•- depicts Zn: leptin, 100 mg/kg, lOO ⁇ l on day 0;
- - ⁇ - depicts a Zn:leptin- containing hydrogel (PLGA/PEG (74%/26% w/w) ) , 20 mg/mL leptin, 100 mg/kg, lOO ⁇ l on day 0.
- % body weight change (from the day 0 body weight) is plotted vs. time (days) .
- Reverse thermal gelation is defined as meaning the temperature below which a copolymer is soluble in water and above which the block copolymer forms a semi -solid, i.e. gels, emulsions, dispersions and suspensions.
- LCST lower critical solution temperature
- LSCT reverse thermal gelation temperature
- Depot is defined as meaning a drug delivery liquid which, following injection into a warm blooded animal, has formed a gel upon having the temperature raised to or above the LCST.
- Biodegradable is defined as meaning that the block copolymer will erode or degrade in vivo to form smaller non- toxic components.
- Parenteral administration is defined as meaning any route of administration other than the alimentary canal, including, for example, subcutaneous and intramuscular.
- the present invention involves utilization of block copolymers having hydrophobic ( "A” ) block segments and hydrophilic (“B”) block segments.
- the block copolymers are triblock copolymers, e.g., ABA or BAB type block copolymers, which possess reverse thermal gelation properties and are biodegradable and biocompatible.
- triblock copolymers of the present invention provide instant gelation and possess the necessary rate of degradation to be commercially useful.
- Biodegradable hydrophobic A block segments contemplated for use include poly ( ⁇ -hydroxy acid) members derived from or selected from the group consisting of homopolymers and copolymers of poly (lactide) s (d,l- or 1- forms), poly (glycolide) s, polyanhydrides, polyorthoesters, polyetheresters, polycaprolactone, polyesteramides, polycarbonate, polycyanoacrylate, polyurethanes , polyacrylate, blends and copolymers thereof .
- PLGA polymer of lactic acid alone, a polymer of glycolic acid alone, a mixture of such polymers, a copolymer of glycolic acid and lactic acid, a mixture of such copolymers, or a mixture of such polymers and copolymers.
- the biodegradable A block polymer will be poly lactide-co-glycolide (PLGA) , and the PLGA composition will be such that the necessary rate of gelation and rate of degradation are obtained.
- the range of molecular weights contemplated for the polymers to be used in the present processes can be readily determined by a person skilled in the art based upon such factors the desired polymer degradation rate.
- the range of molecular weight for the A block will be 1000 to 20,000 Daltons.
- Hydrophilic B block segments contemplated for use include polyethylene glycols having average molecular weights of between about 500 and 10,000.
- the copolymer compositions for the block copolymers of the present invention are specially regulated to assure retention of the desired water- solubility and gelling properties, i.e., the ratios must be such that the block copolymers possess water solubility at temperatures below the LCST, and such that there is instant gelation under physiological conditions (i.e. pH 7.0 and 37°C) so as to minimize the initial burst of drug.
- the hydrophobic A block makes up 55% to 90% by weight of the copolymer and the hydrophilic B block makes up 10% to 45% of the copolymer.
- the concentration at which the block copolymers of the present invention remain soluble below the LCST are generally up to about 60% by weight, with 10%- 30% preferred. The concentration utilized will depend upon the copolymer composition actually used, as well as whether or not a gel or emulsion is desired.
- thermosensitive block copolymers of the present invention can be prepared by thermal condensation.
- A-B-A block copolymers of PLGA/PLA (block A) and PEG (block B) are synthesized by mixing either homopolymer of poly lactide (PLA) or copolymer of poly lactide-co-gycolide (PLGA) with polyethylene glycol (PEG) and allowing di-hydroxy PEG to react with PLGA or PLA at 160°C under reduced pressure.
- Different weight ratios of PLGA and PEG were used for thermal condensation to obtain a series of block copolymers with desirable copolymer composition and block lengths. Copolymer composition and relative block lengths were confirmed by ⁇ H-NMR spectroscopy.
- the copolymers could be synthesized in a melt process which involves ring opening polymerization of A block using B block as the initiator.
- the ABA triblock copolymer is prepared by stannous octoate catalyzed ring-opening polymerization of d, 1-dilactide (or PLGA) using ⁇ , ⁇ -dihydroxy- terminated PEG as the initiator.
- the mole ratio of B block to d, 1-dilactide (or PLGA) is used to control the lengths of the A blocks, and provide a series of polymers with increasing A block contents and hydrophobicites .
- the relative A and B block lengths can be confirmed by ⁇ -NMR spectroscopy.
- the process used to mix the copolymers with a biologically active agent and/or other materials involves dissolving the ABA block copolymers in an aqueous solution, followed by addition of the biologically active agent (in solution, suspension or powder) , followed by thorough mixing to assure a homogeneous mixing of the biologically active agent throughout the copolymer.
- the process can involve the dissolving of the ABA block copolymer in a biologically active agent -containing solution. In either case, the process is conducted at a temperature lower than the gelation temperature of the copolymer and the material is implanted into the body as a solution which then gels or solidifies into a depot in the body.
- the biologically active agent will generally have a concentration in the range of 0 to 200 mg/mL.
- Buffers contemplated for use in the preparation of the biologically active agent -containing hydrogels are buffers which are all well known by those of ordinary skill in the art and include sodium acetate, Tris, sodium phosphate, MOPS, PIPES, MES and potassium phosphate, in the range of 25mM to 500mM and in the pH range of 4.0 to 8.5.
- excipients e.g., various sugars, salts, or surfactants
- the ability to alter the rate of gelation and/or LCST is important and an otherwise non-useful hydrogel may be made useful by addition of such excipients.
- sugars include glucose or sucrose in the range of 5% to 20%.
- salts include sodium chloride or zinc chloride in the range of 0.5% to 10%.
- biologically active agents refers to recombinant or naturally occurring proteins, whether human or animal, useful for prophylactic, therapeutic or diagnostic application.
- the biologically active agent can be natural, synthetic, semi -synthetic or derivatives thereof.
- biologically active agents of the present invention can be perceptible.
- a wide range of biologically active agents are contemplated. These include but are not limited to hormones, cytokines, hematopoietic factors, growth factors, antiobesity factors, trophic factors, anti -inflammatory factors, small molecules and enzymes (see also U.S. Patent No. 4,695,463 for additional examples of useful biologically active agents) .
- Proteins contemplated for use would include but are not limited to interferon consensus (see, U.S. Patent Nos. 5,372,808, 5,541,293 4,897,471, and 4,695,623 hereby incorporated by reference including drawings), interleukins (see, U.S. Patent No. 5,075,222, hereby incorporated by reference including drawings), erythropoietins (see, U.S. Patent Nos. 4,703,008, 5,441,868, 5,618,698 5,547,933, and 5,621,080 hereby incorporated by reference including drawings) , granulocyte-colony stimulating factors (see, U.S. Patent Nos. 4,810,643, 4,999,291, 5,581,476,
- PCT Publication No. 94/17185 hereby incorporated by reference including drawings
- stem cell factor PCT Publication Nos. 91/05795, 92/17505 and 95/17206, hereby incorporated by reference including drawings
- OB protein leptin
- Such protein containing sustained- release compositions could serve to enhance the effectiveness of either exogenously administered or endogenous protein, or could be used, for example, to reduce or eliminate the need for exogenous protein administration.
- the materials utilized in the present invention are biocompatible and biodegradable, use of the protein compositions of the present invention help prevent adverse injection site reactions sometimes associated with i.v. injections of various proteins such as leptin.
- biologically active agents can also include insulin, gastrin, prolactin, adrenocorticotropic hormone (ACTH) , thyroid stimulating hormone (TSH) , luteinizing hormone (LH) , follicle stimulating hormone (FSH) , human chorionic gonadotropin (HCG) , motilin, interferons (alpha, beta, gamma) , tumor necrosis factor (TNF) , tumor necrosis factor-binding protein (TNF-bp) , interleukin- 1 receptor antagonist (IL-lra) , brain derived neurotrophic factor (BDNF) , glial derived neurotrophic factor (GDNF) , neurotrophic factor 3 (NT3) , fibroblast growth factors (FGF) , neurotrophic growth factor (NGF) , bone growth factors such as osteoprotegerin (OPG) , insulin- like growth factors (IGFs) , macrophage colony stimulating factor (M-CSF) ,
- polypeptides with amino acid substitutions which are "conservative" according to acidity, charge, hydrophobicity, polarity, size or any other characteristic known to those skilled in the art. See generally, Creighton, Proteins, W.H. Freeman and Company, N.Y., (1984) 498 pp. plus index, passim. One may make changes in selected amino acids so long as such changes preserve the overall folding or activity of the protein. Small amino terminal extensions, such as an amino- terminal methionine residue, a small linker peptide of up to about 20-25 residues, or a small extension that facilitates purification, such as a poly-histidine tract, an antigenic epitope or a binding domain, may also be present.
- Polypeptides or analogs thereof may also contain one or more amino acid analogs, such as peptidomimetics .
- compositions comprising effective amounts of chemically modified protein, or derivative products, together with pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers needed for administration.
- pharmaceutically acceptable diluents such as a pharmaceutically acceptable diluent, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers needed for administration.
- compositions of the present invention are administered as a liquid via intramuscular or subcutaneous route and undergo a phase change wherein a gel is formed within the body, since the body temperature will be above the gelation temperature of the material.
- the release rates and duration for the particular biologically active agents will be a function of, inter alia , hydrogel density and the molecular weight of the agent.
- Therapeutic uses of the compositions of the present invention depend on the biologically active agent used. One skilled in the art will readily be able to adapt a desired biologically active agent to the present invention for its intended therapeutic uses. Therapeutic uses for such agents are set forth in greater detail in the following publications hereby incorporated by reference including drawings. Therapeutic uses include but are not limited to uses for proteins like interferons (see, U.S. Patent Nos.
- compositions may also be used for manufacture of one or more medicaments for treatment or amelioration of the conditions the biologically active agent is intended to treat.
- sustained- release compositions of the present invention an effective amount of active ingredient will be utilized.
- sustained release refers to the gradual release of active ingredient from the polymer matrix, over an extended period of time.
- the sustained release can be continuous or discontinuous, linear or non- linear, and this can be accomplished using one or more polymer compositions, drug loadings, selection of excipients, or other modifications.
- the sustained release will result in biologically effective serum levels of the active agent (typically above endogenous levels) for a period of time longer than that observed with direct administration of the active agent.
- a sustained release of the active agent will be for a period of a week or more, preferably up to one month.
- PLGA poly Lactic acid-co-Glycolic acid
- PLA poly Lactic acid
- High molecular weight PLGAs were obtained from B.I. Chemicals.
- Polyethylene glycols (PEG) were obtained from Fluka Chemicals.
- Leptin, zinc- leptin, GCSF, Fc-Leptin, and Fc-OPG were obtained from Amgen Inc. All other chemicals are from sources well known in the art.
- This example describes synthesis of a PLGA/PEG, A-B-A (PLGA- PEG- PLGA) , block copolymer by thermal condensation.
- the thermal condensation method is generally depicted in Figure 1.
- the isolated polymer was dried at 40°C under vacuum for 48 hours.
- the molecular weight of the block copolymer was determined by gel permeation chromatography (GPC) using polystyrene standards.
- the copolymer composition and relative block lengths were determined by 'H-NMR.
- LCST critical solution temperature
- This example describes the synthesis of PLGA/PEG, A-B-A (PLGA- PEG- PLGA) , block copolymers using PLGA with different lactic acid to glycolic acid ratios.
- the synthesis and characterization procedures described in Example 1 were utilized to prepare PLGA/PEG block copolymers using PLGA with different LA to GA ratios (see Table 1 below) .
- the block copolymers listed below showed thermoreversibility (Sol-gel-sol) with LCST at about 30°C to 35°C.
- PLA (100%) 45g 17, ,55g 72/28 1.56 1.48 (Mn 3480, MW 6590)
- PLGA 75/25%) 30g 11 .74g 72/28 1.65 1.56 (Mn 3740, MW 7090)
- PLGA 50/50%) 30g 10, .71g 74/26 1.8 1.78 (Mn 3480/MW 6590)
- PLGA (56/44%) 40g 15 .60g 72/28 1.71 1.66 (Mn 3480/MW 6590)
- Example 3 This example describes the synthesis of PLGA/PEG, A-B-A (PLGA- PEG-PLGA) , block copolymers using different weight ratios of PLGA and PEG.
- the synthesis and characterization procedure described in Example 1 were utilized to prepare PLGA/PEG block copolymers with various PLGA to PEG ratios (see Table 2 below) . All of the block copolymers listed below showed thermoreversibility (sol-gel-sol) with LCST in the range of 25°C - 35°C.
- This example describes the preparation of a leptin/hydrogel formulation and the methods used to determine the in vitro release kinetics, in vivo release kinetics, and pharmacokinetics of the leptin/hydrogel .
- leptin/hydrogel formulation The PLGA/PEG block copolymer described in Example 1 was dissolved in 50mM sodium acetate, pH 6.0. Leptin solution (formulated in 20mM acetate, pH 4.8) was slowly added to the hydrogel solution and the mixture was gently swirled on an orbital shaker at 5°C to assure a homogeneous mixing of leptin throughout the hydrogel solution. The final concentration of the copolymer in the final leptin/hydrogel formulation was 10-50% (w/w) and the leptin concentration was in the range of 0-100 mg/ l.
- the final leptin/hydrogel formulation was filtered through 0.2 ⁇ filter and stored either as a solution at 5°C or stored as a frozen mass at -20°C.
- the leptin/hydrogel formulation was prepared by dissolving the PLGA/PEG block copolymer in a leptin solution.
- the leptin solution concentration was varied to obtain desirable copolymer as well as the desired protein concentration in final formulation.
- the in vi tro release of leptin from the leptin/hydrogel was carried out in 20mM sodium phosphate, 5% sorbitol, pH 7.4, at 37°C. 1 ml of leptin/hydrogel solution formulation was placed in a glass vial at 37°C. Upon gelation of the leptin/hydrogel formulation, 1 ml of 20mM phosphate, 5% sorbitol, pH 7.4, buffer was added directly above and in contact with the gel. The amount of leptin released in the top buffer phase was determined by UV spectrophotometer at 280nm as well as by SEC-HPLC at 220nm.
- % body weight change (from the day 0 body weight) was determined by weighing the animals daily until the body weight of the animals injected with sample (b) , (d) and (e) reached the body weights of the animals injected with buffer control (sample (a)).
- a single s.c. injection of 100 mg/kg leptin/hydrogel formulation (sample (d) ) showed sustained weight loss in normal mice over a 10 day period. The duration of sustained weight loss effect was further extended up to 14 days when the dose was increased to 200 mg/kg (sample (e) ) .
- a pharmacokinetics study was carried out in male rats. After a single s.c. injection of either: 1) 100 mg/kg dose of leptin (20 mg/ml) formulated in 20mM acetate buffer, pH 4.8); or 2) a leptin/hydrogel (74/26% (PLGA/PEG) (w/w) ) formulation consisting of 20 mg/ml leptin, in 20mM acetate, pH 4.8, blood samples were collected at various time intervals and analyzed for leptin by ELISA assay. As shown in Figure 5, serum concentrations of leptin were detectable for up to 168 hours for animals injected with the leptin/hydrogel formulation.
- This example describes the incorporation of G-CSF into the hydrogel and the results of in vi tro release studies using the formulation.
- GCSF solution (formulated in lOmM acetate, 5% sucrose, pH 4.0) was added to the copolymer hydrogel solution (formulated in 20mM acetate, pH 6.0) as described in Example 4.
- the final concentration of the copolymer in the GCSF/hydrogel formulation was 10-50% (w/w) and the GCSF concentration was in the range of 1-20 mg/ml.
- the in vi tro release of GCSF from the hydrogel was carried out in 20mM sodium phosphate buffer, pH 7.4, at 37 °C as described in Example 4.
- the % GCSF released over time is shown in Figure 6. As depicted in Figure 6, nearly 100% of the GCSF is released over a 9-10 day period of time.
- the integrity of the GCSF released from the hydrogel formulation was confirmed by HPLC (data not shown) and gel electrophoresis (SDS-PAGE) (see Figure 7) .
- the Fc-OPG/hydrogel formulation was prepared as described in Example 4 by adding Fc-OPG solution (formulated in lOmM sodium acetate, 5% sorbitol, 0.02 mg/ml tween 20, pH 5.0) to the copolymer solution (formulated in 50mM acetate, pH 6.0).
- the in vi tro release of Fc-OPG from the hydrogel was carried out in 20mM sodium phosphate buffer, pH 7.4, at 37°C as described in Example 4.
- the % Fc-OPG released over time is shown in Figure 6. As depicted in Figure 6, nearly 100% of the Fc-OPG is released over a 8-9 day period of time.
- This example describes incorporation of the Zn: leptin suspension into PLGA/PEG hydrogel and the results of in vivo release kinetics of the leptin from the Zn: leptin/hydrogel .
- the PLGA/PEG block polymers described in the examples above were hydrated in lOOmM Tris, pH 8.0 buffer. The final pH of the hydrogel solution was maintained between 6.5 - 7.0 and then a zinc chloride solution was added to the hydrogel to obtain a O.lmM ZnCl 2 concentration in the final hydrogel solution.
- a Zn: leptin suspension was added as described in Example 4.
- the final Zn: leptin concentration in the hydrogel described in this example was 20 mg/ml.
- the in vivo bioactivity of a Zn: leptin/hydrogel (74/26% (PLGA/PEG) (w/w) ) formulation was carried out as described in Example 4. The results of the in vivo bioactivity studies are depicted in Figure 8.
- This example describes the incorporation of Zn:GCSF into the PLGA/PEG hydrogel and the results of in vi tro release studies using the formulation.
- the PLGA/PEG block copolymer described in the examples above was hydrated in lOOmM PIPES, pH 7.5 buffer.
- the final pH of the hydrogel solution was maintained between 6.5 - 7.0 and then a zinc chloride solution was added to the hydrogel to obtain a O.lmM ZnCl 2 concentration in the final hydrogel solution.
- a Zn:GCSF suspension was added as described in Example 4.
- the in vi tro release of GCSF from the hydrogel was carried out in 20mM sodium phosphate buffer, pH 7.4, at 37°C, as described in Example 4. It was demonstrated that sustained release of GCSF could be obtained from these hydrogel formulations.
- the block polymer described in the examples above was hydrated in lOOmM MES, pH 7.5 buffer.
- the final pH of the hydrogel solution was maintained between 6.5 - 7.0 and then a MgCl 2 solution was added to the hydrogel to obtain a 0.2M MgCl 2 concentration in the final hydrogel solution.
- a GCSF crystals suspension was added as described in Example 4.
- the in vi tro release of GCSF from the hydrogel was carried out in 20mM sodium phosphate buffer, pH 7.4, at 37 °C, as described in Example 4. It was demonstrated that sustained release of GCSF could be obtained from these hydrogel formulations.
- This example describes the effect of various excipients on the LCST of PLGA/PLGA, A-B-A block copolymers. As indicated in Table 4 below, the addition of various sugars, salts, surfactants, etc. can effect the rate of gelation and LCST of the hydrogels.
- Polyethylene glycol 4- rate of gelation Increased LCST at 5%-20% Soft gel
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL14026899A IL140268A0 (en) | 1998-06-30 | 1999-06-25 | Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents |
EP99933564A EP1091761A1 (en) | 1998-06-30 | 1999-06-25 | Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents |
KR1020007014945A KR20010053259A (en) | 1998-06-30 | 1999-06-25 | Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents |
CA002335852A CA2335852A1 (en) | 1998-06-30 | 1999-06-25 | Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents |
HU0102803A HUP0102803A3 (en) | 1998-06-30 | 1999-06-25 | Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents |
JP2000556807A JP2002519333A (en) | 1998-06-30 | 1999-06-25 | Thermosensitive biodegradable hydrogels for sustained release delivery of biologically active substances |
AU49599/99A AU754003B2 (en) | 1998-06-30 | 1999-06-25 | Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10733498A | 1998-06-30 | 1998-06-30 | |
US09/107,334 | 1998-06-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000000222A1 true WO2000000222A1 (en) | 2000-01-06 |
WO2000000222A9 WO2000000222A9 (en) | 2000-07-20 |
Family
ID=22316103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/014206 WO2000000222A1 (en) | 1998-06-30 | 1999-06-25 | Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1091761A1 (en) |
JP (1) | JP2002519333A (en) |
KR (1) | KR20010053259A (en) |
CN (1) | CN1321092A (en) |
AU (1) | AU754003B2 (en) |
CA (1) | CA2335852A1 (en) |
HU (1) | HUP0102803A3 (en) |
IL (1) | IL140268A0 (en) |
WO (1) | WO2000000222A1 (en) |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000038651A1 (en) * | 1998-12-23 | 2000-07-06 | Amgen Inc. | BIODEGRADABLE pH/THERMOSENSITIVE HYDROGELS FOR SUSTAINED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS |
WO2001041735A2 (en) * | 1999-12-07 | 2001-06-14 | Amgen Inc. | Thermosensitive biodegradable hydrogels based on low molecular weight pluronics |
WO2001068768A1 (en) * | 2000-03-15 | 2001-09-20 | Cheng Yu Ling | Environment responsive gelling copolymer |
WO2003070218A1 (en) * | 2002-02-19 | 2003-08-28 | Sunstar Inc. | Sustained-release ointment for topical administration |
KR100434439B1 (en) * | 2000-04-11 | 2004-06-04 | 이재민 | A Method on Preparation of W/O/W Multple Emulsions Stabilized by Poly/Poly Block Copolymer |
EP1446423A2 (en) * | 2001-06-14 | 2004-08-18 | MacroMed, Inc. | Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
KR100488002B1 (en) * | 2001-06-20 | 2005-05-09 | 주식회사 삼양사 | Amphiphilic block copolymer consisting of hydrophilic polyalkylene glycol block and hydrophobic block, copolymer of aromatic side chain - containing α-hydroxyl acid derivatives and lactides |
US7008633B2 (en) | 2000-12-18 | 2006-03-07 | Board Of Regents, The University Of Texas System | Local regional chemotherapy and radiotherapy using in situ hydrogel |
KR100560069B1 (en) * | 2002-11-29 | 2006-03-13 | 주식회사 태평양 | Biodegradable amphiphilic block copolymers and a method for preparing thereof |
US7160931B2 (en) | 2000-03-15 | 2007-01-09 | Yu-Ling Cheng | Thermally reversible implant and filler |
US7193007B2 (en) | 2000-03-15 | 2007-03-20 | Yu-Ling Cheng | Environment responsive gelling copolymer |
US7223826B2 (en) | 2003-01-30 | 2007-05-29 | 3M Innovative Properties Company | Amide-functional polymers, compositions, and methods |
EP1807018A2 (en) * | 2004-10-21 | 2007-07-18 | University of Iowa Research Foundation | In situ controlled release drug delivery system |
US7714077B2 (en) | 2003-07-07 | 2010-05-11 | Nof Corporation | Triblock copolymer, method for producing the same, and biocompatible material |
WO2010079305A1 (en) | 2009-01-07 | 2010-07-15 | Polymerexpert Sa | Anti-snoring composition containing a thermogelling polymer |
WO2012054923A3 (en) * | 2010-10-22 | 2012-07-05 | Bind Biosciences, Inc. | Therapeutic nanoparticles with high molecular weight copolymers |
US8318208B1 (en) | 2008-06-16 | 2012-11-27 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8357401B2 (en) | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
US8460707B2 (en) | 2004-08-05 | 2013-06-11 | Ferring B.V. | Stabilised prostaglandin composition |
US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
WO2014053542A1 (en) | 2012-10-02 | 2014-04-10 | Dsm Ip Assets B.V. | Drug delivery composition comprising proteins and biodegradable polyesteramides |
US8900556B2 (en) | 2003-01-30 | 2014-12-02 | 3M Innovative Properties Company | Hardenable thermally responsive compositions |
US8912212B2 (en) | 2009-12-15 | 2014-12-16 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
US9198874B2 (en) | 2008-12-15 | 2015-12-01 | Bind Therapeutics, Inc. | Long circulating nanoparticles for sustained release of therapeutic agents |
US9351933B2 (en) | 2008-06-16 | 2016-05-31 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
US9408785B2 (en) | 2012-10-15 | 2016-08-09 | L'oreal | Hair styling compositions containing aqueous wax dispersions |
US9579284B2 (en) | 2008-06-16 | 2017-02-28 | Pfizer Inc. | Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same |
US9877923B2 (en) | 2012-09-17 | 2018-01-30 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
US9895378B2 (en) | 2014-03-14 | 2018-02-20 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same |
US9987364B2 (en) | 2002-09-27 | 2018-06-05 | Ferring B.V. | Water-swellable polymers |
US10105445B2 (en) | 2006-07-05 | 2018-10-23 | Ferring B.V. | Hydrophilic polyurethane compositions |
RU2693042C2 (en) * | 2015-04-20 | 2019-07-01 | Тгель Био Ко., Лтд. | Drug delivery kit, and device and method for preparing drug delivery system |
US10413496B2 (en) | 2012-10-15 | 2019-09-17 | L'oreal | Aqueous wax dispersions |
US10561596B2 (en) | 2014-04-11 | 2020-02-18 | L'oreal | Compositions and dispersions containing particles comprising a polymer |
US10626294B2 (en) | 2012-10-15 | 2020-04-21 | L'oreal | Aqueous wax dispersions containing volatile solvents |
FR3091996A1 (en) | 2019-01-24 | 2020-07-31 | Les Laboratoires Brothier | HEALING COMPOSITION |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1296097C (en) * | 2003-02-25 | 2007-01-24 | 吴建梅 | Polymer micelle medicine-carrying system |
CN100427144C (en) * | 2005-12-30 | 2008-10-22 | 复旦大学 | Degradable temperature sensitive physical aquagel and its preparation method |
MX2009002985A (en) * | 2006-09-19 | 2009-04-01 | Genzyme Corp | Formulations for therapeutic administration of thyroid stimulating hormone (tsh). |
CN101333295B (en) * | 2007-06-27 | 2011-01-05 | 中国科学院化学研究所 | Biodegradable high molecular nanometer particles, special polymer thereof and preparation method thereof |
JP5989126B2 (en) * | 2011-10-17 | 2016-09-07 | ポリ−メド インコーポレイテッド | Absorbent in-situ gel-forming system, its production method and its use |
CA2885169C (en) * | 2012-10-11 | 2021-06-22 | Ascendis Pharma A/S | Diagnosis, prevention and treatment of diseases of the joint |
WO2014088319A1 (en) | 2012-12-06 | 2014-06-12 | 주식회사 엘지화학 | Lactide copolymer, and resin composition and film comprising same |
CN104837889B (en) | 2012-12-06 | 2016-10-26 | Lg化学株式会社 | Lactide copolymer, prepare the method for this lactide copolymer and comprise the resin combination of this lactide copolymer |
JP6176998B2 (en) * | 2013-05-13 | 2017-08-09 | 学校法人 関西大学 | Temperature-responsive biodegradable polymer composition and method for producing the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997015287A1 (en) * | 1995-10-25 | 1997-05-01 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester) block copolymers |
WO1999018142A1 (en) * | 1997-10-03 | 1999-04-15 | Macromed, Inc. | BIODEGRADABLE LOW MOLECULAR WEIGHT TRIBLOCK POLY(LACTIDE-co-GLYCOLIDE) POLYETHYLENE GLYCOL COPOLYMERS HAVING REVERSE THERMAL GELATION PROPERTIES |
-
1999
- 1999-06-25 CA CA002335852A patent/CA2335852A1/en not_active Abandoned
- 1999-06-25 AU AU49599/99A patent/AU754003B2/en not_active Ceased
- 1999-06-25 EP EP99933564A patent/EP1091761A1/en not_active Withdrawn
- 1999-06-25 KR KR1020007014945A patent/KR20010053259A/en not_active Application Discontinuation
- 1999-06-25 CN CN99810059A patent/CN1321092A/en active Pending
- 1999-06-25 HU HU0102803A patent/HUP0102803A3/en unknown
- 1999-06-25 IL IL14026899A patent/IL140268A0/en unknown
- 1999-06-25 WO PCT/US1999/014206 patent/WO2000000222A1/en not_active Application Discontinuation
- 1999-06-25 JP JP2000556807A patent/JP2002519333A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997015287A1 (en) * | 1995-10-25 | 1997-05-01 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester) block copolymers |
US5702717A (en) * | 1995-10-25 | 1997-12-30 | Macromed, Inc. | Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers |
WO1999018142A1 (en) * | 1997-10-03 | 1999-04-15 | Macromed, Inc. | BIODEGRADABLE LOW MOLECULAR WEIGHT TRIBLOCK POLY(LACTIDE-co-GLYCOLIDE) POLYETHYLENE GLYCOL COPOLYMERS HAVING REVERSE THERMAL GELATION PROPERTIES |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000038651A1 (en) * | 1998-12-23 | 2000-07-06 | Amgen Inc. | BIODEGRADABLE pH/THERMOSENSITIVE HYDROGELS FOR SUSTAINED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS |
WO2001041735A2 (en) * | 1999-12-07 | 2001-06-14 | Amgen Inc. | Thermosensitive biodegradable hydrogels based on low molecular weight pluronics |
WO2001041735A3 (en) * | 1999-12-07 | 2001-12-13 | Amgen Inc | Thermosensitive biodegradable hydrogels based on low molecular weight pluronics |
US7160931B2 (en) | 2000-03-15 | 2007-01-09 | Yu-Ling Cheng | Thermally reversible implant and filler |
WO2001068768A1 (en) * | 2000-03-15 | 2001-09-20 | Cheng Yu Ling | Environment responsive gelling copolymer |
US7193007B2 (en) | 2000-03-15 | 2007-03-20 | Yu-Ling Cheng | Environment responsive gelling copolymer |
KR100434439B1 (en) * | 2000-04-11 | 2004-06-04 | 이재민 | A Method on Preparation of W/O/W Multple Emulsions Stabilized by Poly/Poly Block Copolymer |
US7008633B2 (en) | 2000-12-18 | 2006-03-07 | Board Of Regents, The University Of Texas System | Local regional chemotherapy and radiotherapy using in situ hydrogel |
EP1446423A2 (en) * | 2001-06-14 | 2004-08-18 | MacroMed, Inc. | Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
EP1446423A4 (en) * | 2001-06-14 | 2010-07-21 | Protherics Salt Lake City Inc | Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders |
KR100488002B1 (en) * | 2001-06-20 | 2005-05-09 | 주식회사 삼양사 | Amphiphilic block copolymer consisting of hydrophilic polyalkylene glycol block and hydrophobic block, copolymer of aromatic side chain - containing α-hydroxyl acid derivatives and lactides |
WO2003070218A1 (en) * | 2002-02-19 | 2003-08-28 | Sunstar Inc. | Sustained-release ointment for topical administration |
US9987364B2 (en) | 2002-09-27 | 2018-06-05 | Ferring B.V. | Water-swellable polymers |
KR100560069B1 (en) * | 2002-11-29 | 2006-03-13 | 주식회사 태평양 | Biodegradable amphiphilic block copolymers and a method for preparing thereof |
US7223826B2 (en) | 2003-01-30 | 2007-05-29 | 3M Innovative Properties Company | Amide-functional polymers, compositions, and methods |
US8900556B2 (en) | 2003-01-30 | 2014-12-02 | 3M Innovative Properties Company | Hardenable thermally responsive compositions |
US7714077B2 (en) | 2003-07-07 | 2010-05-11 | Nof Corporation | Triblock copolymer, method for producing the same, and biocompatible material |
US8709482B2 (en) | 2004-08-05 | 2014-04-29 | Ferring B.V. | Stabilised prostaglandin composition |
US8460707B2 (en) | 2004-08-05 | 2013-06-11 | Ferring B.V. | Stabilised prostaglandin composition |
EP1807018A4 (en) * | 2004-10-21 | 2012-07-04 | Univ Iowa Res Found | In situ controlled release drug delivery system |
US8940311B2 (en) | 2004-10-21 | 2015-01-27 | Tae-Hong Lim | In situ controlled release drug delivery system |
EP1807018A2 (en) * | 2004-10-21 | 2007-07-18 | University of Iowa Research Foundation | In situ controlled release drug delivery system |
US10105445B2 (en) | 2006-07-05 | 2018-10-23 | Ferring B.V. | Hydrophilic polyurethane compositions |
US9579386B2 (en) | 2008-06-16 | 2017-02-28 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US9351933B2 (en) | 2008-06-16 | 2016-05-31 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
US8318208B1 (en) | 2008-06-16 | 2012-11-27 | Bind Biosciences, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US9579284B2 (en) | 2008-06-16 | 2017-02-28 | Pfizer Inc. | Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same |
US9393310B2 (en) | 2008-06-16 | 2016-07-19 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US9375481B2 (en) | 2008-06-16 | 2016-06-28 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
US8905997B2 (en) | 2008-12-12 | 2014-12-09 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
US9198874B2 (en) | 2008-12-15 | 2015-12-01 | Bind Therapeutics, Inc. | Long circulating nanoparticles for sustained release of therapeutic agents |
US9308179B2 (en) | 2008-12-15 | 2016-04-12 | Bind Therapeutics, Inc. | Long circulating nanoparticles for sustained release of therapeutic agents |
WO2010079305A1 (en) | 2009-01-07 | 2010-07-15 | Polymerexpert Sa | Anti-snoring composition containing a thermogelling polymer |
US8956657B2 (en) | 2009-12-11 | 2015-02-17 | Bind Therapeutics, Inc. | Stable formulations for lyophilizing therapeutic particles |
US8357401B2 (en) | 2009-12-11 | 2013-01-22 | Bind Biosciences, Inc. | Stable formulations for lyophilizing therapeutic particles |
US8916203B2 (en) | 2009-12-11 | 2014-12-23 | Bind Therapeutics, Inc. | Stable formulations for lyophilizing therapeutic particles |
US9872848B2 (en) | 2009-12-11 | 2018-01-23 | Pfizer Inc. | Stable formulations for lyophilizing therapeutic particles |
US9295649B2 (en) | 2009-12-15 | 2016-03-29 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
US8912212B2 (en) | 2009-12-15 | 2014-12-16 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
US9835572B2 (en) | 2009-12-15 | 2017-12-05 | Pfizer Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
WO2012054923A3 (en) * | 2010-10-22 | 2012-07-05 | Bind Biosciences, Inc. | Therapeutic nanoparticles with high molecular weight copolymers |
US9877923B2 (en) | 2012-09-17 | 2018-01-30 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
WO2014053542A1 (en) | 2012-10-02 | 2014-04-10 | Dsm Ip Assets B.V. | Drug delivery composition comprising proteins and biodegradable polyesteramides |
US9408785B2 (en) | 2012-10-15 | 2016-08-09 | L'oreal | Hair styling compositions containing aqueous wax dispersions |
US10413496B2 (en) | 2012-10-15 | 2019-09-17 | L'oreal | Aqueous wax dispersions |
US10626294B2 (en) | 2012-10-15 | 2020-04-21 | L'oreal | Aqueous wax dispersions containing volatile solvents |
US10888504B2 (en) | 2012-10-15 | 2021-01-12 | L'oreal | Hair styling compositions containing aqueous wax dispersions |
US10071100B2 (en) | 2014-03-14 | 2018-09-11 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same |
US9895378B2 (en) | 2014-03-14 | 2018-02-20 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same |
US10561596B2 (en) | 2014-04-11 | 2020-02-18 | L'oreal | Compositions and dispersions containing particles comprising a polymer |
RU2693042C2 (en) * | 2015-04-20 | 2019-07-01 | Тгель Био Ко., Лтд. | Drug delivery kit, and device and method for preparing drug delivery system |
US10391233B2 (en) | 2015-04-20 | 2019-08-27 | Tgel Bio Co., Ltd. | Drug delivery kit, and apparatus and method for preparing drug delivery system |
FR3091996A1 (en) | 2019-01-24 | 2020-07-31 | Les Laboratoires Brothier | HEALING COMPOSITION |
EP3698768A1 (en) | 2019-01-24 | 2020-08-26 | Les Laboratoires Brothier | Healing composition |
Also Published As
Publication number | Publication date |
---|---|
HUP0102803A2 (en) | 2001-11-28 |
WO2000000222A9 (en) | 2000-07-20 |
CN1321092A (en) | 2001-11-07 |
CA2335852A1 (en) | 2000-01-06 |
JP2002519333A (en) | 2002-07-02 |
EP1091761A1 (en) | 2001-04-18 |
AU754003B2 (en) | 2002-10-31 |
HUP0102803A3 (en) | 2004-06-28 |
IL140268A0 (en) | 2002-02-10 |
KR20010053259A (en) | 2001-06-25 |
AU4959999A (en) | 2000-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU754003B2 (en) | Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents | |
US6541033B1 (en) | Thermosensitive biodegradable hydrogels for sustained delivery of leptin | |
CA2355657C (en) | Biodegradable ph/thermosensitive hydrogels for sustained delivery of biologically active agents | |
EP1143929B1 (en) | BIODEGRADABLE pH/THERMOSENSITIVE HYDROGELS FOR SUSTAINED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | |
US6004573A (en) | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties | |
KR100633939B1 (en) | Biodegradable low molecular weight triblock polylactide-??-glycolide polyethylene glycol copolymers having reverse thermal gelation properties | |
US6117949A (en) | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties | |
US6201072B1 (en) | Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties | |
EP0863745B1 (en) | Thermosensitive biodegradable polymers based on poly(ether-ester) block copolymers | |
WO2001041735A2 (en) | Thermosensitive biodegradable hydrogels based on low molecular weight pluronics | |
MXPA00012892A (en) | Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents | |
MXPA01006292A (en) | BIODEGRADABLE pH/THERMOSENSITIVE HYDROGELS FOR SUSTAINED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99810059.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/8-8/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 140268 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 49599/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/012892 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2335852 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2000 556807 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007014945 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999933564 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999933564 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007014945 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 49599/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999933564 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007014945 Country of ref document: KR |